Anika Therapeutics, Inc. (ANIK) Q3 FY2026 earnings

Reported results

• Total revenue for the third quarter was $30.6 million, up 10% year over year.
• Gross margin was 62%, compared with 56% in the prior-year period.
• GAAP loss from continuing operations was $0.3 million, or $0.02 per diluted share.
• Non-GAAP adjusted net income from continuing operations was $3.9 million, or $0.29 per diluted share.
• Non-GAAP adjusted EBITDA was $5.1 million.
• Commercial Channel revenue was $14.0 million, up approximately 17% year over year, while OEM Channel revenue was $16.6 million, up approximately 5% year over year.

Guidance

• Full-year 2026 Total Company revenue growth: 6% to 10%
• Full-year 2026 OEM Channel revenue growth: 5% to 9%
• Full-year 2026 Commercial Channel revenue growth: 9% to 13%
• Full-year 2026 non-GAAP Adjusted EBITDA margin: 15% to 17%
• Full-year 2027 Total Company revenue growth: Flat to 5%
• Full-year 2027 OEM Channel revenue growth: Flat to modestly lower
• Full-year 2027 Commercial Channel revenue growth: 5% to 15%

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.